Review
Immunology
Sunghark Kwon
Summary: JAKs are important enzymes in the JAK-STAT signaling pathway, and dysfunctional JAKs can lead to severe immune system-related diseases. Various JAK inhibitors have been developed to block abnormal JAK-STAT signaling, but drug selectivity and resistance to these inhibitors remain challenges. This review discusses the role and structure of JAKs, as well as strategies for disrupting JAK dimerization to develop novel inhibitors.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Obstetrics & Gynecology
Sachiko Matsuzaki, Jean-Luc Pouly, Michel Canis
Summary: Persistent activation of signal transducer and activator of transcription 3 (STAT3) via interleukin-6 (IL-6) trans-signaling is involved in fibrosis of endometriosis.
HUMAN REPRODUCTION
(2022)
Article
Biochemistry & Molecular Biology
Feng Zhou, Fanyun Zhu, Tianru Zhu, Zhucheng Zhao, Luyao Li, Shichong Lin, Haiyang Zhao, Lehe Yang, Chengguang Zhao, Liangxing Wang, Jifa Li, Xiaoying Huang
Summary: AT7519, a CDK inhibitor, exhibits great anti-tumor effects in lung cancer by blocking IL-6/STAT3 pathway and inhibiting cell proliferation and inducing apoptosis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Review
Biochemistry & Molecular Biology
Jia Liu, Faping Wang, Fengming Luo
Summary: There are four members of the JAK family and seven of the STAT family in mammals. The JAK/STAT molecular pathway can be activated by various hormones, cytokines, growth factors, etc. The JAK/STAT signaling pathway extensively mediates various biological processes such as cell proliferation, differentiation, migration, apoptosis, and immune regulation.
Article
Pharmacology & Pharmacy
Ge Jin, Lintao Wang, Jun Ma
Summary: Cardiac hypertrophy is a compensatory response to chronic pressure overload, and excessive angiotensin II plays a significant role in inducing cardiac hypertrophy. Previous studies have shown that STAT5, a member of the STATs family, is closely linked to non-tumor diseases, but its specific role in hypertrophy progression remains unclear. In this study, STAT5-IN-1, a STAT5 inhibitor, was administered to mice and H9c2s cells were used as cell models to investigate the effects of STAT5-IN-1 on cardiac hypertrophy induced by angiotensin II. The findings demonstrated that STAT5 inhibitor substantially decreased cardiac hypertrophy by reducing inflammation.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Geriatrics & Gerontology
Yoseph Toni Wijaya, Tania Setiawan, Ita Novita Sari, Keunwan Park, Chan Hee Lee, Kae Won Cho, Yun Kyung Lee, Jae-Young Lim, Jeong Kyo Yoon, Sae Hwan Lee, Hyog Young Kwon
Summary: Ginsenoside Rd (GRd) significantly ameliorates muscle wasting induced by aging and cancer through various mechanisms, demonstrating a potential therapeutic role in reversing muscle wasting in mice.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Article
Endocrinology & Metabolism
An-Ci Siao, Li-Jane Shih, Yen-Yue Lin, Yi-Wei Tsuei, Yow-Chii Kuo, Hui-Chen Ku, Chih-Ping Chuu, Po-Jen Hsiao, Yung-Hsi Kao
Summary: ET-3 stimulates white preadipocyte growth through the ETAR, AMPK, JNK/c-JUN, and STAT3 pathways, showing a preadipocyte type-dependent effect. These findings provide insights into how endothelin mediates fat cell activity and associated diseases.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Chemistry, Medicinal
Lin Deng, Jianshan Mo, Yi Zhang, Keren Peng, Huaxuan Li, Shumin Ouyang, Zongbo Feng, Wei Fang, Jianwei Wei, Deqin Rong, Xiaolei Zhang, Yuanxiang Wang
Summary: Research has shown that targeting the STAT3-SH2 domain with a boronic acid group has the potential to be a new strategy for treating various human diseases. By replacing the carboxylic acid with a boronic acid, a highly potent inhibitor with stronger anticancer effects has been identified.
JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Chemistry, Medicinal
Ko-Hua Yu, Chin-Chuan Hung, Tian-Shung Wu, Chin-Fu Chen, I-Ting Wu, Ping-Chung Kuo, Sio-Hong Lam, Hsin-Yi Hung
Summary: Research has shown that zhankuic acid methyl ester derivatives have better chemoreversal activity in multidrug-resistant cancer cells, with compound 12 exhibiting the highest reversal fold. Compounds 8, 12, and 26 were found to influence the activation of STAT3, contributing to their chemoreversal effects. These findings suggest a new potential combined therapy with paclitaxel for treating multidrug-resistant cancers.
Article
Chemistry, Multidisciplinary
Jingjing Wang, Zixuan Huang, Li Ji, Cheng Chen, Quan Wan, Yu Xin, Zhening Pu, Koukou Li, Jiantong Jiao, Ying Yin, Yaling Hu, Lingli Gong, Rui Zhang, Xusheng Yang, Xiangming Fang, Mei Wang, Bo Zhang, Junfei Shao, Jian Zou
Summary: The study identified SH2 domain-containing adapter protein F (SHF) as a tumor suppressor in glioblastoma Multiforme (GBM), which negatively regulates STAT3 activity. Additionally, peptide C16 derived from SHF shows remarkable growth inhibition in GBM cells.
Review
Cell Biology
Yun Liu, Shijie Liao, Samuel Bennett, Haijun Tang, Dezhi Song, David Wood, Xinli Zhan, Jiake Xu
Summary: STAT3, a key protein involved in cell growth, differentiation, and survival, is overexpressed in osteosarcoma and various cancers. Its constitutive activation leads to upregulation of oncogenes, affecting processes such as transformation, proliferation, and metastasis.
CELL PROLIFERATION
(2021)
Article
Cell Biology
Camilla Bjornbak Holst, Henriette Pedersen, Elisabeth Anne Adanma Obara, Kristoffer Vitting-Seerup, Kamilla Ellermann Jensen, Jane Skjoth-Rasmussen, Eva Lobner Lund, Hans Skovgaard Poulsen, Julia Sidenius Johansen, Petra Hamerlik
Summary: In the study, the challenges in treating GBM patients were explored, including the frustrations brought by anti-angiogenic agents and immunotherapy, the historical trajectory of bevacizumab as a treatment modality, and the role of dual targeting strategies in therapy. The study emphasizes that pursuing pleiotropic targets and leaning toward multitarget strategies may be key to more effective therapeutic intervention in GBM.
Article
Chemistry, Medicinal
Atsunori Kaneshige, Longchuan Bai, Mi Wang, Donna McEachern, Jennifer L. Meagher, Renqi Xu, Paul D. Kirchhoff, Bo Wen, Duxin Sun, Jeanne A. Stuckey, Shaomeng Wang
Summary: We discovered a potent and selective STAT5 degrader with strong antitumor activity in vivo. Using PROTAC technology, we transformed small-molecule ligands into selective STAT5 degraders, with AK-2292 as the best compound. AK-2292 effectively induced degradation of STAT5 proteins in AML cell lines and showed strong antitumor activity in mice.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Infectious Diseases
Zhao-Ming Chen, Xiao-Yun Yang, Zheng-Tu Li, Wei-Jie Guan, Ye Qiu, Shao-Qiang Li, Yang-Qing Zhan, Zi-Ying Lei, Jing Liu, Jian-Quan Zhang, Zhong-Fang Wang, Feng Ye
Summary: The presence of anti-IFN-gamma autoantibodies inhibits immune responses of CD4(+) Th1 and CD8(+) T cells, and increases the release of IL-10.
INFECTION AND DRUG RESISTANCE
(2022)
Article
Medicine, Research & Experimental
Jiameng Lu, Xiaoqing Ji, Lixia Wang, Fei Sun, Chuanjun Huang, Haiying Peng, Yunxiu Jiang, Zihan Guo, Xinyi Liu, Yanbo Ji, Degan Lu
Summary: This study found that prophylactic administration of IL-27 can improve asthma by restoring the STAT1 and STAT3 pathways, alleviating the Th2 inflammatory environment in the lungs.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
(2022)
Review
Oncology
Shoichi Deguchi, Koichi Mitsuya, Yoko Nakasu, Nakamasa Hayashi, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Mitsuru Takahashi, Masahiro Endo
INVESTIGATIONAL NEW DRUGS
(2018)
Article
Clinical Neurology
Koichi Mitsuya, Yoko Nakasu, Takeshi Kurakane, Nakamasa Hayashi, Hideyuki Harada, Kazuhiko Nozaki
JOURNAL OF NEUROSURGERY
(2017)
Article
Clinical Neurology
Takeo Uzuka, Hideaki Takahashi, Yoko Nakasu, Takeshi Okuda, Koichi Mitsuya, Nakamasa Hayashi, Takayuki Hirose, Hanako Kurai
NEUROLOGIA MEDICO-CHIRURGICA
(2017)
Meeting Abstract
Oncology
Eriko Miyawaki, Hirotsugu Kenmotsu, Hideyuki Harada, Koichi Mitsuya, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Yoko Nakasu, Toshiaki Takahashi
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Article
Multidisciplinary Sciences
Koichi Mitsuya, Yoko Nakasu, Nakamasa Hayashi, Shoichi Deguchi, Toshiaki Takahashi, Haruyasu Murakami, Tateaki Naito, Hirotsugu Kenmotsu, Akira Ono, Kazushige Wakuda, Hideyuki Harada
Article
Oncology
Akira Iizuka, Chizu Nonomura, Tadashi Ashizawa, Ryota Kondou, Keiichi Ohshima, Takashi Sugino, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu, Kouji Maruyama, Ken Yamaguchi, Yasuto Akiyama
CLINICAL CANCER RESEARCH
(2019)
Article
Immunology
Chizu Nonomura, Masaki Otsuka, Ryota Kondou, Akira Iizuka, Haruo Miyata, Tadashi Ashizawa, Naoki Sakura, Shusuke Yoshikawa, Yoshio Kiyohara, Keiichi Ohshima, Kenichi Urakami, Takeshi Nagashima, Sumiko Ohnami, Masatoshi Kusuhara, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu, Tohru Mochizuki, Ken Yamaguchi, Yasuto Akiyama
IMMUNOLOGY LETTERS
(2019)
Article
Oncology
Eriko Miyawaki, Hirotsugu Kenmotsu, Keita Mori, Hideyuki Harada, Koichi Mitsuya, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Yoko Nakasu, Yasuhiro Gon, Toshiaki Takahashi
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Review
Oncology
Koichi Mitsuya, Yoko Nakasu, Shoichi Deguchi, Kensei Shirata, Koiku Asakura, Kazuaki Nakashima, Masahiro Endo, Toshiaki Takahashi, Nakamasa Hayashi
Review
Oncology
Junichiro Watanabe, Koichi Mitsuya, Shogo Nakamoto, Hideyuki Harada, Shoichi Deguchi, Nakamasa Hayashi, Yoko Nakasu
Summary: Management of leptomeningeal metastasis from estrogen receptor-positive, HER2-negative advanced breast cancer remains challenging, necessitating a multimodal approach with novel systemic therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Shoichi Deguchi, Koichi Mitsuya, Kazuaki Yasui, Keisuke Kimura, Tsuyoshi Onoe, Hirofumi Ogawa, Hirofumi Asakura, Hideyuki Harada, Nakamasa Hayashi
Summary: This study retrospectively reviewed the clinical data of 20 patients with BM who underwent neoadjuvant FSRT followed by piecemeal resection, showing that neoadjuvant FSRT may be a safe and effective treatment approach. Postoperative complications were rare, and rates of local and distant recurrence varied.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Letter
Clinical Neurology
Tatsuro Maehara, Ayako Yamazaki, Yoshiko Nakano, Satoshi Nakata, Kohei Fukuoka, Shoichi Deguchi, Koichi Mitsuya, Nakamasa Hayashi, Takuma Oishi, Yuko Kakuda, Takashi Sugino, Koichi Ichimura, Hideaki Yokoo, Sumihito Nobusawa
Article
Clinical Neurology
Yoshiki Sato, Koichi Mitsuya, Yuko Kakuda, Takuma Oishi, Shoichi Deguchi, Takashi Sugino, Yasuto Akiyama, Takeshi Nagashima, Kenichi Urakami, Yuji Shimoda, Keiichi Ohshima, Nakamasa Hayashi, Ken Yamaguchi
Summary: Primary intraosseous meningioma is a rare tumor arising in the skull, generally described as a slow-growing, benign lesion. However, in rare cases, it can present as a malignancy with high proliferative ability, requiring maximal resection, adjuvant radiotherapy, and careful follow-up.
JOURNAL OF NEUROLOGICAL SURGERY REPORTS
(2023)
Review
Oncology
Yoko Nakasu, Shoichi Deguchi, Satoshi Nakasu, Mutsumi Yamazaki, Akifumi Notsu, Koichi Mitsuya, Nakamasa Hayashi
Summary: This study evaluated the diagnostic accuracy of liquid biopsy and magnetic resonance imaging (MRI) as novel CSF biomarkers for detecting leptomeningeal metastases in patients with solid cancers. The results suggest that these new CSF liquid biopsy and MRI methods may offer improved diagnostic accuracy, but further research is needed to determine threshold values and establish specific standards.
NEURO-ONCOLOGY ADVANCES
(2023)
Article
Oncology
Koichi Mitsuya, Yasuto Akiyama, Akira Iizuka, Haruo Miyata, Shoichi Deguchi, Nakamasa Hayashi, Chie Maeda, Ryota Kondou, Akari Kanematsu, Kyoko Watanabe, Tadashi Ashizawa, Yoshiaki Abe, Ichiro Ito, Takuma Oishi, Takashi Sugino, Yoko Nakasu, Ken Yamaguchi
ANTICANCER RESEARCH
(2020)